in both inhibitory and bactericidal testing , the combination of ciprofloxacin with a beta-lactam agent ( ceftazidime , piperacillin , mezlocillin , azlocillin , or imipenem ) was more likely to show a synergistic effect or additive effect and lack of antagonism ( 96.5 % of all inhibitory and cidal tests ) than was a combination of ciprofloxacin with an aminoglycoside [ ( amikacin , tobramycin , or gentamicin ) , 90 % of all inhibitory and cidal tests ] .
C0002556
aminoglycoside
C0040341
tobramycin